Scientists may have identified a pair of epilepsy syndrome patterns and their link to autoimmune illnesses. The single-center study was carried out between January 2016 and December 2020 and involved patients at a tertiary epilepsy center.
During this period, the researchers gathered data from 242 patients suffering from mesial temporal lobe epilepsy with hippocampal sclerosis and 422 patients with idiopathic generalized epilepsies (IGEs). The researchers observed that, on average, patients who suffered from idiopathic generalized epilepsies were more than a decade younger than those with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS)
They also noted that autoimmune disease prevalence across the sample stood at 5%.
The researchers determined that roughly one in three patients with idiopathic generalized epilepsies had been diagnosed with an autoimmune illness before being diagnosed with epilepsy. This was different when MTLE-HS patients were observed, as all but one of them had been diagnosed with epilepsy before receiving their autoimmune illness diagnosis.
This discovery, the scientists explained, highlighted the different relationship patterns that the aforementioned epilepsy syndromes had with autoimmune illnesses, with MTLE-HSE having a unidirectional association and IGEs having a bidirectional association. They added that the links between autoimmune illnesses and epilepsy could be a result of the contrasting etiopathogenetic mechanisms underlying seizure development in each syndrome.
In their report, the researchers explained that the inflammatory mechanisms they observed in patients with mesial temporal lobe epilepsy with hippocampal sclerosis could trigger an autoimmune response and cause autoimmune illnesses to develop in vulnerable patients. They then noted that, with regard to MTLE-HS, learning more about this link could help develop treatment approaches that targeted tissue-specific inflammatory processes to help prevent inflammation and worsening inflammation that could lead to development of autoimmune illnesses.
The researchers also found that the most common manifestation of the disease was skin manifestation, observing this in almost 64% of MTLE-HS patients and 57% of IGEs patients. This is in addition to discovering that connective tissue disorders were less common in patients with IGEs, in comparison to those with MTLE-HS.
The researchers noted in their report that their research represented progress toward better understanding the different links among these comorbid conditions.
The study’s findings were reported in “Epileptic Disorders.” The researchers involved include João Chaves, Ana Sardoeira, Bárbara Leal, Raquel Samões, Vanessa Carvalho, Rui Chorão, Joel Freitas, Sandra Brás, Ana Marta Ferreira, João Ramalheira, João Lopes, Paulo Pinho Costa, Carolina Lemos, Berta Martins da Silva, António Martins da Silva and António Marinho.
The toll taken by autoimmune conditions is rising every year, but there is hope that for-profit companies such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) could soon avail novel immunotherapies to help in the management of these ailments.
NOTE TO INVESTORS: The latest news and updates relating to BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
